Patents Issued in March 17, 2020
-
Patent number: 10590374Abstract: Described herein is an improved automatic bioreactor system utilizing a multi-tray or multi-plate cell culture vessel for cultivating adherent cells.Type: GrantFiled: April 17, 2018Date of Patent: March 17, 2020Inventors: Timothy Ray Ho, Lewis Ho
-
Patent number: 10590375Abstract: The present disclosure relates to methods for control of cell growth rates where cell growth is measured in situ. The methods are applicable to bacterial cells, mammalian cells, non-mammalian eukaryotic cells, plant cells, yeast cells, fungi, and archea.Type: GrantFiled: August 27, 2019Date of Patent: March 17, 2020Assignee: Inscripta, Inc.Inventors: Don Masquelier, Phillip Belgrader
-
Patent number: 10590376Abstract: A system and method for conditioning a tissue are provided. The system includes a substrate, a plurality of microwells formed in the substrate, and a microsphere associated with each of the plurality of microwells. The system also includes a pair of flexible pillars within each of the plurality of microwells. Each flexible pillar includes a first end bonded to a respective microwell and at least one flexible pillar has a second end bonded to the microsphere. The flexible pillars are configured to deflect when exposed to a magnetic field to controllably stretch microtissue spanning the flexible pillars.Type: GrantFiled: November 20, 2015Date of Patent: March 17, 2020Assignee: The Johns Hopkins UniversityInventors: Daniel H. Reich, Fan Xu, Ruogang Zhao, Alan S. Liu, Tristin Metz, Yu Shi
-
Patent number: 10590377Abstract: A multi-function cooling and thermo-sensitive rack includes horizontal bars, a base, positioning holes, connectors, a lateral frame, connecting holes, a temperature-displaying prompter, and N temperature sensors. The lateral frame and the base are connected through the connectors. The lateral frame and the base have their surfaces facing each other symmetrically provided with plural connecting holes thereon. The horizontal bars have two ends thereof received in the corresponding symmetrical connecting holes. The positioning holes are distributed over the surface of the base. The N temperature sensors have output ends thereof for outputting sensing signals connected with input ends of the temperature-displaying prompter for inputting the N temperature-sensing signals. The present invention is applied to apparatuses used in microbiology experiment.Type: GrantFiled: January 29, 2018Date of Patent: March 17, 2020Assignee: HEBEI UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Xiaohui Zhou, Le Xu, Jun Liu, Hao Liu
-
Patent number: 10590378Abstract: A cell separation chip for separating cells from a solution containing the cells includes an upper plate, a membrane positioned on a predetermined region of the upper plate, and an absorption device positioned at a lower end of the upper plate so as to absorb a solution which has penetrated the membrane from the solution containing the cells. There is an effect of effectively collecting/separating only cells in a solution by absorbing the solution containing the cells without the need of applying and maintaining additional external voltage.Type: GrantFiled: April 11, 2016Date of Patent: March 17, 2020Assignee: FERRAMED INC.Inventor: Seyl Kim
-
Patent number: 10590379Abstract: A novel method of growing fungi is disclosed which uses an engineered artificial media and produces high density filamentous fungi biomats that can be harvested with a minimum of processing and from which fungal products such as antibiotics, proteins, and lipids can be isolated, the method resulting in lowered fungus cultivation costs for energy usage, oxygenation, water usage and waste stream production.Type: GrantFiled: June 14, 2019Date of Patent: March 17, 2020Assignee: Sustainable Bioproducts, Inc.Inventors: Mark A. Kozubal, Richard E. Macur, Yuval C. Avniel
-
Patent number: 10590380Abstract: The present invention provides a culture method of cells and/or tissues including culturing cells and/or tissues in a suspended state by using a medium composition wherein indeterminate structures are formed in a liquid medium, the structures are uniformly dispersed in the solution and substantially retain the cells and/or tissues without substantially increasing the viscosity of the solution, thus affording an effect of preventing sedimentation thereof, and the like.Type: GrantFiled: March 2, 2017Date of Patent: March 17, 2020Assignees: Nissan Chemical Industries, Ltd., Kyoto UniversityInventors: Taito Nishino, Tatsuro Kanaki, Ayako Otani, Koichiro Saruhashi, Misayo Tomura, Takehisa Iwama, Masato Horikawa, Norio Nakatsuji, Tomomi Otsuji
-
Patent number: 10590381Abstract: The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.Type: GrantFiled: July 28, 2017Date of Patent: March 17, 2020Assignee: Celularity, Inc.Inventors: James W. Edinger, Mohammad Heidaran, Wolfgang Hofgartner
-
Patent number: 10590382Abstract: The present invention is of methods of establishing and propagating human embryonic stem cell lines using feeder cells-free, xeno-free culture systems and stem cells which are capable of being maintained in an undifferentiated, pluripotent and proliferative state in culture which is free of xeno contaminants and feeder cells.Type: GrantFiled: September 3, 2018Date of Patent: March 17, 2020Assignee: Technion Research & Development Foundation LimitedInventors: Michal Amit, Joseph Itskovitz-Eldor
-
Patent number: 10590383Abstract: Methods are provided, in some aspects, for differentiating pluripotent cells into midbrain dopaminergic (DA) neurons using a mono-SMAD inhibition or inhibition of SMAD signaling with only one SMAD inhibitor. In some embodiments, mono-SMAD inhibition utilizes a single inhibitor of bone morphogenic protein (BMP) for differentiating pluripotent cells into midbrain DA neurons.Type: GrantFiled: August 16, 2017Date of Patent: March 17, 2020Assignee: FUJIFILM Cellular Dynamics, Inc.Inventors: Christopher W. McMahon, Lauren E. Little, Wen Bo Wang, Nathaniel A. Elliott
-
Patent number: 10590384Abstract: The present disclosure relates to luterial, which is a mitochondrial-like unidentified nano-sized particle derived from a body fluid, and to a method for isolating the same.Type: GrantFiled: June 26, 2017Date of Patent: March 17, 2020Assignee: LUTERION CO., LTD.Inventors: Won Cheol Choi, Young Ah Kwon, Suk Hoon Choi, Chang Hoon Choi
-
Patent number: 10590385Abstract: A method for producing natural killer cells is disclosed. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from a blood sample; isolating at least one of CD56+ cells and/or CD3?/CD56+ cells from the PBMCs; and co-culturing the at least one of CD56+ cells and/or CD3?/CD56+ cells with a combination of feeder cells in the presence of a cytokine. A composition for treating cancer is also disclosed. The composition comprises the CD56+ natural killer cells produced by the disclosed method and a cytokine.Type: GrantFiled: July 26, 2019Date of Patent: March 17, 2020Assignee: NKMAX CO., LTD.Inventors: Sang Woo Park, Yong Man Kim, Jae Seob Jung, Yong-Hee Rhee
-
Patent number: 10590386Abstract: The present invention discloses novel compositions and methods for enhancing cardiac differentiation efficiency of stem cells or promoting ventricular and atrial cardiomyocytes formation from stem cells. The present invention also discloses the atrial and ventricular cardiomyocytes formed from the stem cells, and the uses of the cardiomyocytes for repairing cardiac injuries and screening for new medicaments for treating cardiac injuries.Type: GrantFiled: October 28, 2015Date of Patent: March 17, 2020Assignee: INSITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCESInventor: Yue Ma
-
Patent number: 10590387Abstract: Provided herein are isolated CD133+ cells, such as human CD133+ cells, that have been expanded in culture and populations of isolated CD133+ cells that have been expanded in culture. The cells express transcription factors, growth factors, or a combination thereof, at altered levels compared to a naturally occurring CD133+ cell. Also provided are methods, including methods for expanding CD133+ cells and methods for using CD133+ cells.Type: GrantFiled: April 15, 2016Date of Patent: March 17, 2020Assignee: The Board of Regents of The University of Texas SystemInventors: Larry Denner, Randall J. Urban, Yvonne Bodenburg
-
Patent number: 10590388Abstract: The present invention relates to a method for culturing bone marrow cells, in which bone marrow cells are applied to a porous polyimide film and cultured. Moreover, the present invention relates to a porous polyimide film for healing a bone injury site.Type: GrantFiled: January 26, 2016Date of Patent: March 17, 2020Assignees: UBE INDUSTRIES, LTD., KURUME UNIVERSITYInventors: Keisuke Ohta, Shingo Hirashima, Masahiko Hagihara, Motohisa Shimizu
-
Patent number: 10590389Abstract: The present invention provides an endodermal cell production method that can induce differentiation of pluripotent cells into endodermal cells even when the pluripotent cells are dispersed and can achieve improved endodermal cell production efficiency. The endodermal cell production method according to the present invention is a method for producing endodermal cells by inducing differentiation of pluripotent cells into the endodermal cells, including the step of: inducing differentiation of the pluripotent cells into the endodermal cells in the presence of an endodermal cell inducing factor. In the induction step, the cell density of the pluripotent cells at the start of the induction preferably is from 0.5×104 to 2×104 cells/cm2.Type: GrantFiled: December 22, 2015Date of Patent: March 17, 2020Assignee: Kyoto UniversityInventors: Kenichiro Kamei, Momoko Honda
-
Patent number: 10590390Abstract: The present invention relates to a method for preparing highly pure pancreatic progenitor cells by using pluripotent stem cells such as ES cells or iPS cells as a source, inducing their differentiation into pancreatic progenitor cells, and culturing and proliferating the pancreatic progenitor cells. Specifically, the present invention relates to a method for proliferation of pancreatic progenitor cells, comprising the step of culturing the pancreatic progenitor cells in a medium containing (i) an EGF signal transduction activator and/or an FGF signal transduction activator and (ii) a ROCK inhibitor.Type: GrantFiled: August 3, 2015Date of Patent: March 17, 2020Assignee: Takeda Pharmaceutical Company LimitedInventor: Yuya Kunisada
-
Patent number: 10590391Abstract: Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein the cells have been expanded in vitro. The kidney cells preferably produce erythropoietin (EPO). The kidney cells may also be selected based upon EPO production. Methods of producing an isolated population of EPO producing cells are also provided, and methods of treating a kidney disease resulting in decreased EPO production in a patient in need thereof are provided, including administering the population to the patient, whereby the cells express EPO in vivo in an oxygen tension-dependent manner.Type: GrantFiled: November 13, 2009Date of Patent: March 17, 2020Assignee: WAKE FOREST UNIVERSITY HEALTH SCIENCESInventors: Anthony Atala, James J. Yoo
-
Patent number: 10590392Abstract: The technology described herein relates to methods and kits for directed differentation of primordial NKX2-1+ lung progenitors along proximal differentiation pathways into functional airway epithelial cells and airway organoids (“bronchospheres”) or along distal lineage pathways using modulation of Wnt signaling. Other aspects relate cell lines, methods, assays and kits comprising airway epithelial cells, and assays for diagnosing a disease that affects swelling of the bronchospheres, and/or for assessing genetic lesions and/or drugs for treating the the disease, where the disease is cystic fibrosis. Other aspects relate to personalized medicine and methods of treatment of cystic fibrosis using the airway epithelial cells.Type: GrantFiled: January 9, 2018Date of Patent: March 17, 2020Assignee: TRUSTEES OF BOSTON UNIVERSITYInventors: Darrell N. Kotton, Katherine B. McCauley, Finn Hawkins
-
Patent number: 10590393Abstract: In one embodiment, the present invention is a method of creating a fully-human blood-brain barrier (BBB) model, comprising the steps of (a) obtaining a mixture of neural cells and brain microvascular endothelial cells (BMECs), wherein the neural cells and BMECs that comprise the mixture were produced from the differentiation of human pluripotent stem cells (hPSCs); (b) purifying BMECs from the mixture of neural cells and BMECs of step (a); and (c) co-culturing the purified BMECs with a cell type selected from the group consisting of pericytes, astrocytes and differentiated neural progenitor cells (NPCs), wherein a blood brain barrier model is created.Type: GrantFiled: March 11, 2013Date of Patent: March 17, 2020Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Eric V. Shusta, Sean P. Palecek, Ethan S. Lippmann, Samira M. Azarin
-
Patent number: 10590394Abstract: A method of non-covalently loading a plant picornavirus is described. The method includes contacting a plant picornavirus in solution with a molar excess of a cargo molecule to load the plant picornavirus with the cargo molecule, and then purifying the loaded plant picornavirus. Examples of cargo molecules include imaging agents, antitumor agents, and antiviral agents. Loaded plant picornaviruses prepared in this manner can be used to delivering cargo molecule to cells.Type: GrantFiled: February 18, 2014Date of Patent: March 17, 2020Assignee: CASE WESTERN RESERVE UNIVERSITYInventors: Nicole Steinmetz, Daniel Popkin
-
Patent number: 10590395Abstract: Provided is a mutant protein obtained by mutating a specific amino acid residue of HMGR, a rate-limiting enzyme of isoprene monomer biosynthesis in the polyisoprenoid biosynthesis pathway. The present invention relates to a mutant protein, wherein at least one amino acid residue selected from the group consisting of amino acid residues at positions 91, 225, 257, 287, 339, 411, 470, 509 and 574 of the Arabidopsis thaliana 3-hydroxy-3-methylglutaryl CoA reductase shown by SEQ ID NO:1 and amino acid residues at positions corresponding to the foregoing in 3-hydroxy-3-methylglutaryl CoA reductase is deleted or replaced with another amino acid residue.Type: GrantFiled: May 22, 2015Date of Patent: March 17, 2020Assignees: OSAKA UNIVERSITY, SUMITOMO RUBBER INDUSTRIES, LTD.Inventors: Keiko Suzuki, Jekson Robertlee, Toshiya Muranaka, Keiji Takagi, Yukino Inoue, Kazuhisa Fushihara
-
Patent number: 10590396Abstract: The disclosure relates to engineered ketoreductase polypeptides and processes of using the polypeptides for production of phenylephrine.Type: GrantFiled: June 11, 2019Date of Patent: March 17, 2020Assignee: Codexis, Inc.Inventors: Oscar Alvizo, Steven J. Collier, Hans-Georg Joerg Hennemann, Seong Ho Oh, Wenjuan Zha
-
Patent number: 10590397Abstract: Compositions and methods for increasing resistance to Fusarium infection in plants are provided herein. Polynucleotides, polypeptides, and expression constructs for expressing mutant UDP-glycosyltransferase proteins, plants comprising the polynucleotides, polypeptides or expression constructs, and methods of producing transgenic plants are also provided.Type: GrantFiled: March 2, 2018Date of Patent: March 17, 2020Assignee: Wisconsin Alumni Research FoundationInventors: Ivan Rayment, Karl Wetterhorn
-
Patent number: 10590398Abstract: Phototropin is a blue light receptor, which mediates a variety of blue-light elicited physiological processes in plants and algae. In higher plants these processes include phototropism, chloroplast movement and stomatal opening. In the green alga Chlamydomonas reinhardtii, phototropin plays a vital role in progression of the sexual life cycle and in the control of the eye spot size and light sensitivity Phototropin is also involved in blue-light mediated changes in the synthesis of chlorophylls, carotenoids, chlorophyll binding proteins. We compared the transcriptome of phototropin knock out (PHOT KO) mutant and wild-type parent to analyze differences in gene expression in high light grown cultures (500 ?mol photons m?2 s?1). Our results indicate the up-regulation of genes involved in photosynthetic electron transport chain, carbon fixation pathway, starch, lipid, and cell cycle control genes.Type: GrantFiled: December 4, 2017Date of Patent: March 17, 2020Assignees: NMC, INC., LOS ALAMOS NATIONAL SECURITY, LLCInventors: Sangeeta Negi, Richard Thomas Sayre, Shawn Robert Starkenburg
-
Patent number: 10590399Abstract: A DNA polymerase mutant comprising a Taq DNA polymerase amino acid sequence with a mutation at one or more of the following selected amino acid positions: E189K, E230K, E507K, H28R, L30R, G38R, F73V, H75R, E76A, E76G, E76K, E90K, K206R, E315K, A348V, L351F, A439T, D452N, G504S, E507A, D551N, L552R, I553V, D578N, H676R, Q680R, D732G, E734G, E734K, F749V; wherein the polymerase mutant exhibits relative to wild-type DNA polymerase increased polymerase speed, increased affinity to DNA substrate and/or increased resistance to a DNA polymerase inhibitor; and wherein, when the mutation is E507K in combination with two or more further mutations or the mutation is Q680R in combination with four or more further mutations, at least one of the further mutations is at one of the selected amino acid positions; and when the mutation is I553V, this is not in combination with D551S.Type: GrantFiled: September 29, 2016Date of Patent: March 17, 2020Assignee: Thermo Fisher Scientific Baltics UABInventors: Remigijus Skirgaila, Agne Tubelevic̆iūtē, Renata Rims̆eliēnē, Sigitas Burinskas
-
Patent number: 10590400Abstract: Disclosed are mutant DNA polymerases having increased 3?-mismatch discrimination relative to a corresponding, unmodified polymerase. The mutant polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the mutant DNA polymerases.Type: GrantFiled: January 4, 2018Date of Patent: March 17, 2020Assignee: Roch Molecular Systems, Inc.Inventors: Keith Bauer, Fred Reichert, Thomas W. Myers
-
Patent number: 10590401Abstract: The present invention relates to novel esterase, more particularly to esterase variants having improved activity compared to the esterase of SEQ ID NO: 1 and the uses thereof for degrading polyester containing material, such as plastic products. The esterases of the invention are particularly suited to degrade polyethylene terephthalate, and material containing polyethylene terephthalate.Type: GrantFiled: July 12, 2017Date of Patent: March 17, 2020Assignee: CARBIOSInventors: Vincent Tournier, Helene Texier, Marie-Laure Desrousseaux, Christopher Topham, Isabelle Andre, Sophie Barbe, Sophie Duquesne, Alain Marty
-
Patent number: 10590402Abstract: Disclosed is a combination of two or more lipase enzymes, and its use for treating a lipid digestion deficiency and/or a digestive disorder. At least one lipase enzyme has a pH optimum at an acidic pH value, while at least one other lipase enzyme has a pH optimum at an alkalic pH value.Type: GrantFiled: January 22, 2016Date of Patent: March 17, 2020Assignee: CILIAN AGInventors: Marcus Wolf William Hartmann, Ingo Aldag
-
Patent number: 10590403Abstract: Acinetobacter lysin polypeptides and variants peptides with killing activity against gram negative bacteria. Methods for treating bacterial infections or bacterial colonization using Acinetobacter lysin polypeptides.Type: GrantFiled: June 26, 2015Date of Patent: March 17, 2020Assignee: The Rockefeller UniversityInventors: Vincent Fischetti, Raymond Schuch, Rolf Lood, Benjamin Winer
-
Patent number: 10590404Abstract: The present invention pertains to the field of amylases with reduced disposition to form deamidation products, particularly alpha-amylases, and compositions comprising such amylases. Also described are means and methods for producing such amylases, and uses of amylases and amylase-comprising compositions, for example for cleaning starch-containing stains, textile desizing, starch liquefaction and saccharification, baking and brewing. The invention also discloses means for increasing amylase purity during fermentation, formulation and storage of amylase or amylase-containing formulations.Type: GrantFiled: April 15, 2015Date of Patent: March 17, 2020Assignee: BASF SEInventors: Stefan Jenewein, Stefan Niedermaier
-
Patent number: 10590405Abstract: A process for producing blood coagulation Factor VII in 3 human cell lines (HepG2, Sk-Hep, HKB-11) and to select the best recombinant protein producer is described. The murine line BHK-21 was used as control. The data allow to assert that the system used to modify cell lines was efficient, so that all the cells were satisfactorily modified, and produced the protein of interest of stable form. In addition, when comparing the murine line BHK-21 with the human cells (HepG2, Sk-Hep-1 and HKB-11), the latter showed to be able to produce rFVII more efficiently, which allows to conclude that human cell lines are a great alternative for the production of recombinant blood coagulation factors.Type: GrantFiled: April 27, 2016Date of Patent: March 17, 2020Assignee: FUNDAÇÃO HEMOCENTRO DE RIBEIRÃO PRETO—FUNDHERPInventors: Dimas Tadeu Covas, Marcela Cristina Corrêa de Freitas, Virginia Picanço e Castro, Kamilla Swiech
-
Patent number: 10590406Abstract: The invention provides a recombinant, carboxydotrophic Clostridium bacterium that expresses one or more of pyruvate:ferredoxin oxidoreductase (EC 1.2.7.1), acetolactate synthase (EC 2.2.1.6), and acetolactate decarboxylase (EC 4.1.1.5). The invention further provides a method of producing a fermentation product by fermenting the recombinant bacterium in the presence of a gaseous substrate comprising CO to produce one or more of ethanol, butanol, isopropanol, isobutanol, higher alcohols, butanediol, 2,3-butanediol, succinate, isoprenoids, fatty acids, biopolymers, and mixtures thereof.Type: GrantFiled: December 7, 2015Date of Patent: March 17, 2020Assignee: LANZATECH NEW ZEALAND LIMITEDInventors: Michael Koepke, Alexander Paul Mueller, Loan Phuong Tran
-
Patent number: 10590407Abstract: The present invention is directed to enzymes having Asx-specific ligase and cyclase activity and to nucleic acids encoding those as well as methods of the manufacture of said enzymes. Further encompassed are methods and uses of these enzymes.Type: GrantFiled: March 24, 2015Date of Patent: March 17, 2020Assignee: Nanyang Technological UniversityInventors: Kien Truc Giang Nguyen, James P. Tam
-
Patent number: 10590408Abstract: The present invention relates to biomolecule stabilization to provide biomolecules, such as sensitive polymerases, in a convenient ready-to-go format. The invention provides a method and composition in which non-ionic surfactant or detergents of the polyoxyethylene cetyl ether family are used, preferably a Brij reagent or a combination of Brij reagents.Type: GrantFiled: February 10, 2017Date of Patent: March 17, 2020Assignee: GE Healthcare UK LimitedInventors: Peter James Tatnell, Elizabeth Mary Ashman
-
Patent number: 10590409Abstract: A method and a device are provided for facilitating the disaggregation of a plurality of solid phase substrate as the plurality of solid phase substrate are transferred from a first location to a second location. A plurality of solid phase substrate are deposited at the first location and a plurality of particles are added to the plurality of solid phase substrate. A force is generated to draw the plurality of solid phase substrate from the first location to a second location. The plurality of particles causes clumps of the plurality of solid phase substrate to break apart as the plurality of solid phase substrate are moved in response to the force.Type: GrantFiled: December 6, 2016Date of Patent: March 17, 2020Assignee: Wisconsin Alumni Research FoundationInventors: David J. Beebe, David J. Guckenberger, Jr., Hannah M. Pezzi
-
Patent number: 10590410Abstract: Methods for processing polynucleotide-containing biological samples, and materials for capturing polynucleotide molecules such as RNA and/or DNA from such samples are provided. The RNA and/or DNA is captured by polyamindoamine (PAMAM (Generation 0)) bound to a surface, such as the surface of magnetic particles. The methods and materials have high efficiency of binding RNA and of DNA, and of release, and thereby permit quantitative determinations. The binding particles can be coated with PAMAM (Generation 0) dendrimer which is amide-bonded to the binding particles, wherein at least a portion of the nucleic acids in the biological sample become reversibly bonded to the binding particles.Type: GrantFiled: October 12, 2018Date of Patent: March 17, 2020Assignee: HANDYLAB, INC.Inventors: Sundaresh N. Brahmasandra, Elizabeth Craig
-
Patent number: 10590411Abstract: The invention relates to methods for the detection of a specific sequence of RNA in a cell or tissue sample. The invention also relates to methods to enzymatically manipulate the RNA in a crude cell lysate in a number of applications.Type: GrantFiled: March 8, 2019Date of Patent: March 17, 2020Assignee: APPLIED BIOSYSTEMS, LLCInventors: Brittan Pasloske, Quoc Hoang
-
Patent number: 10590412Abstract: Disclosed herein are compounds, compositions and methods for modulating the amount or activity of a target nucleic acid. In certain embodiments, the amount or activity of a target nucleic acid is modulated through nonsense mediated decay.Type: GrantFiled: April 21, 2014Date of Patent: March 17, 2020Assignee: Ionis Pharmaceuticals, Inc.Inventors: Amanda Ward, Frank Rigo
-
Patent number: 10590413Abstract: The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.Type: GrantFiled: March 17, 2017Date of Patent: March 17, 2020Assignee: WAVE LIFE SCIENCES LTD.Inventors: David Charles Donnell Butler, Naoki Iwamoto, Meena, Nenad Svrzikapa, Gregory L. Verdine, Ivan Zlatev
-
Patent number: 10590414Abstract: The disclosed subject matter relates to brush polymer-oligonucleotide conjugates comprising oligonucleotides covalently attached to the backbone of a non-cationic, sterically congested brush polymer and the use of such polymer-oligonucleotide conjugates in antisense gene regulation and as diagnostic agents.Type: GrantFiled: August 4, 2016Date of Patent: March 17, 2020Assignee: NORTHEASTERN UNIVERSITYInventors: Ke Zhang, Xueguang Lu
-
Patent number: 10590415Abstract: The present disclosure provides engineered Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising these nucleic acids, and compositions thereof. Nucleic acid sequences encoding the Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising such nucleic acids, and compositions thereof.Type: GrantFiled: October 18, 2017Date of Patent: March 17, 2020Assignee: Ceribou Biosciences, Inc.Inventors: Paul Daniel Donohoue, Andrew Paul May
-
Patent number: 10590416Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of an alpha-ENaC (SCNN1A) gene. The alpha-ENaC RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an alpha-ENaC gene. Pharmaceutical compositions that include one or more alpha-ENaC RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described alpha-ENaC RNAi agents to epithelial cells, such as pulmonary epithelial cells, in vivo, provides for inhibition of alpha-ENaC gene expression and a reduction in ENaC activity, which can provide a therapeutic benefit to subjects, including human subjects.Type: GrantFiled: July 5, 2018Date of Patent: March 17, 2020Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Zhen Li, Rui Zhu, Tao Pei, Anthony Nicholas, Erik W Bush
-
Patent number: 10590417Abstract: Disclosed herein are compositions comprising extracellular vesicles, such as exosomes, displaying an RNA nanoparticle on its surface. The RNA nanoparticle can target the extracellular vesicle to a given cell via a targeting moiety. The extracellular vesicle can also comprise a functional moiety, which can be used in treatment or diagnostics.Type: GrantFiled: October 5, 2018Date of Patent: March 17, 2020Assignee: Ohio State Innovation FoundationInventors: Peixuan Guo, Fengmei Pi, Hui Li, Shaoying Wang
-
Patent number: 10590418Abstract: Methods and compositions are provided for modulating, e.g., reducing, viral coding sequence expression in mammals and mammalian cells. In the subject methods, an effective amount of an RNAi agent, e.g., an interfering ribonucleic acid (such as an siRNA or shRNA) or a transcription template thereof, e.g., a DNA encoding an shRNA, is introduced into a target cell, e.g., by being administered to a mammal that includes the target cell, e.g., via a hydrodynamic administration protocol. Also provided are RNAi agent pharmaceutical preparations for use in the subject methods. The subject methods and compositions find use in a variety of different applications, including academic and therapeutic applications.Type: GrantFiled: September 27, 2002Date of Patent: March 17, 2020Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Mark A. Kay, Anton McCaffrey
-
Patent number: 10590419Abstract: The invention relates to compostions and methods for promoting cellular proliferation and de-differentiation of cells into stem cells to foster tissue regeneration. Specifically, the invention relates to transiently administering a microRNA (miR) or its mimic for promoting cardiomyocyte proliferation and cardiac regeneration.Type: GrantFiled: May 15, 2015Date of Patent: March 17, 2020Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventor: Edward E. Morrisey
-
Patent number: 10590420Abstract: The invention relates to a method for the treatment of amyotrophic lateral sclerosis (ALS). Specifically, the invention implements the use of an antisense sequence adapted to affect alternative splicing in a human SOD1 pre-mRNA, thereby leading to the destruction of the skipped m RNA by the cell machinery.Type: GrantFiled: July 31, 2015Date of Patent: March 17, 2020Assignees: ASSOCIATION INSTITUT DE MYOLOGIE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)Inventors: Martine Barkats, Maria-Grazia Biferi, Thomas Voit
-
Patent number: 10590421Abstract: Described are methods for removing a proteolytic cleavage site, the HCHWA-D mutation or the amino acids encoded by a trinucleotide repeat expansion from a protein comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that comprises the proteolytic cleavage site, HCHWA-D mutation or trinucleotide repeat expansion, respectively, the method further comprising allowing translation of mRNA produced from the pre-mRNA.Type: GrantFiled: April 21, 2017Date of Patent: March 17, 2020Assignee: Academisch Ziekenhuis Leiden H.O.D.N. LUMCInventors: Wilhelmina M. C. van Roon-Mom, Melvin Maurice Evers, Barry Antonius Pepers, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
-
Patent number: 10590422Abstract: The present invention is directed to a method of treating cancer using interfering RNA duplexes to mediate gene silencing. The present invention is also directed to interfering RNA duplexes and vectors encoding such interfering RNA duplexes.Type: GrantFiled: June 14, 2017Date of Patent: March 17, 2020Assignee: PHYZAT BIOPHARMACEUTICALS, LDA.Inventor: Patricio Soares da Silva
-
Patent number: 10590423Abstract: In certain aspects, provided herein are RNA complexes that inhibit Myeloid differentiation primary response gene 88 (MyD88) and/or Toll-like receptor 3 (TLR3) and are useful in the treatment of age-related macular degeneration (AMD). In certain aspects, provided herein are pharmaceutical compositions comprising such RNA complexes and methods of using such RNA complexes and pharmaceutical compositions.Type: GrantFiled: July 23, 2018Date of Patent: March 17, 2020Assignee: OliX Pharmaceuticals, Inc.Inventors: Dong-ki Lee, Sun Woo Hong, Isu Hong, Jihye Hwang